ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries

Overview

This is a randomized, within-subject controlled study to compare the clinical performance of the ReCell device when used as an adjunct to meshed skin graft in subjects requiring skin grafts for closure of burn injuries. Co-primary effectiveness endpoints include: (1) confirmed treatment area closure (i.e., healing) prior to or at 8 weeks as assessed by a blinded evaluator, and (2) a comparison of the actual expansion ratio, computed as the ratio of measured treated area to the measured donor site area, achieved for the ReCell-treated and control treatment areas. Safety will be evaluated in terms of long-term durability, scar outcomes and treatment-related adverse events.

Full Title of Study: “Demonstration of the Safety and Effectiveness of ReCell® Combined With Meshed Skin Graft for Reduction of Donor Area in the Treatment of Acute Burn Injuries”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 21, 2016

Interventions

  • Device: ReCell Treatment
  • Procedure: Skin Graft

Arms, Groups and Cohorts

  • Experimental: All Participants (within patient control)
    • All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants With Confirmed Treatment Area Closure of RECELL-treated Wounds Compared to Control (Non-inferiority)
    • Time Frame: Prior to or at 8 weeks
    • Complete wound closure is defined as skin re-epithelialization without drainage, confirmed at two consecutive study visits at least 2 weeks apart by direct visualization by a qualified clinician blinded to treatment assignment. The incidence of complete wound closure is hypothesized to be non-inferior for RECELL-treated areas as compared to control areas.
  • Actual Expansion Ratios (Treatment Area to Donor Site Area, Inclusive of Donor Skin Needed for Secondary Treatments)
    • Time Frame: Prior to or at 8 weeks
    • For this second co-primary endpoint, it is hypothesized that the expansion ratio associated with the RECELL treatment area will be superior to that of the control, i.e. less donor skin will be required for RECELL-treated areas compared with the control areas.

Secondary Measures

  • Observer Overall Patient and Observer Scar Assessment Scale ( POSAS) Opinion Score
    • Time Frame: At 24 Week
    • The observer component of the Patient and Observer Scar Assessment Scale (POSAS) questionnaire required the blinded evaluator to provide an overall opinion of the treatment area compared to normal skin, scored from 1 (normal skin) to 10 (worst imaginable scar).
  • Patient’s Satisfaction/Treatment Preference
    • Time Frame: At 24 Week
  • Patient Overall Patient and Observer Scar Assessment Scale (POSAS) Opinion Score
    • Time Frame: Week 24
    • The patient component of the Patient Overall Patient and Observer Scar Assessment Scale (POSAS) questionnaire required the patient to provide an overall opinion of the treatment area compared to normal skin, scored from 1 (normal skin) to 10 (worst imaginable scar). T

Participating in This Clinical Trial

Inclusion Criteria

1. The subject requires skin grafting as a result of an acute thermal burn injury (i.e. injuries caused by exposure of the skin to fire/flames, excessive heat, hot steam or water). 2. The area of total burn injury is 5-50% TBSA inclusive. 3. Two areas requiring skin grafting, each at least 300cm2 (or 600cm2 contiguous), excluding hand/face and joints. 4. The subject is at least 5 years of age. 5. The subject (or family, for those under 18 years of age) is willing and able to complete all followup evaluations required by the study protocol. 6. The subject is to abstain from any other treatment of the wound(s) for the duration of the study unless medically necessary. 7. The subject agrees to abstain from enrollment in any other interventional clinical trial for the duration of the study. 8. The subject and/or guardian are able to read and understand instructions and give informed, voluntary, written consent. Exclusion Criteria:

1. The subject's burn injuries were caused by chemicals, electricity, and/or radioactive substances. 2. The subject is unable to follow the protocol. 3. The subject has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives. 4. The subject has a known hypersensitivity to trypsin or compound sodium lactate for irrigation (Hartmann's) solution. 5. Life expectancy is less than 1 year.

Gender Eligibility: All

Minimum Age: 5 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Avita Medical
  • Collaborator
    • MedDRA Assistance Inc
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • James H Holmes, IV, MD, Principal Investigator, Wake Forest University Health Sciences

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.